Liu X - Search Results

1

Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal-Organic Framework for Alzheimer's Disease Therapy.

Zhao J, Yin F, Ji L, Wang C, Shi C, Liu X, Yang H, Wang X, Kong L. Zhao J, et al. Among authors: liu x. ACS Appl Mater Interfaces. 2020 Oct 7;12(40):44447-44458. doi: 10.1021/acsami.0c11064. Epub 2020 Sep 16. ACS Appl Mater Interfaces. 2020. PMID: 32897042

2

Identification and optimization of piperlongumine analogues as potential antioxidant and anti-inflammatory agents via activation of Nrf2.

Ji L, Qu L, Wang C, Peng W, Li S, Yang H, Luo H, Yin F, Lu D, Liu X, Kong L, Wang X. Ji L, et al. Among authors: liu x. Eur J Med Chem. 2021 Jan 15;210:112965. doi: 10.1016/j.ejmech.2020.112965. Epub 2020 Oct 27. Eur J Med Chem. 2021. PMID: 33148493

3

Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.

Qu L, Ji L, Wang C, Luo H, Li S, Peng W, Yin F, Lu D, Liu X, Kong L, Wang X. Qu L, et al. Among authors: liu x. Eur J Med Chem. 2021 Jul 5;219:113441. doi: 10.1016/j.ejmech.2021.113441. Epub 2021 Apr 7. Eur J Med Chem. 2021. PMID: 33862517

4

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.

Wang C, Qu L, Li S, Yin F, Ji L, Peng W, Luo H, Lu D, Liu X, Chen X, Kong L, Wang X. Wang C, et al. Among authors: liu x. J Med Chem. 2021 Sep 9;64(17):12630-12650. doi: 10.1021/acs.jmedchem.1c00567. Epub 2021 Aug 29. J Med Chem. 2021. PMID: 34455779

5

Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease.

Qu L, Li S, Ji L, Luo S, Ding M, Yin F, Wang C, Luo H, Lu D, Liu X, Peng W, Kong L, Wang X. Qu L, et al. Among authors: liu x. Eur J Med Chem. 2021 Dec 15;226:113889. doi: 10.1016/j.ejmech.2021.113889. Epub 2021 Oct 2. Eur J Med Chem. 2021. PMID: 34649182

6

Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer.

Liu X, Wang C, Li S, Qu L, Yin F, Lu D, Luo H, Chen X, Luo Z, Cui N, Wang X, Kong L. Liu X, et al. J Med Chem. 2021 Dec 9;64(23):17304-17325. doi: 10.1021/acs.jmedchem.1c01380. Epub 2021 Nov 30. J Med Chem. 2021. PMID: 34847663

7

Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy.

Lu D, Qu L, Wang C, Luo H, Li S, Yin F, Liu X, Chen X, Luo Z, Cui N, Peng W, Ji L, Kong L, Wang X. Lu D, et al. Among authors: liu x. Bioorg Chem. 2022 Mar;120:105604. doi: 10.1016/j.bioorg.2022.105604. Epub 2022 Jan 12. Bioorg Chem. 2022. PMID: 35051708

8

Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.

Wang C, Chen X, Liu X, Lu D, Li S, Qu L, Yin F, Luo H, Zhang Y, Luo Z, Cui N, Kong L, Wang X. Wang C, et al. Among authors: liu x. Eur J Med Chem. 2022 Aug 5;238:114462. doi: 10.1016/j.ejmech.2022.114462. Epub 2022 May 20. Eur J Med Chem. 2022. PMID: 35623249

9

Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.

Lu D, Wang C, Qu L, Yin F, Li S, Luo H, Zhang Y, Liu X, Chen X, Luo Z, Cui N, Kong L, Wang X. Lu D, et al. Among authors: liu x. J Med Chem. 2022 Oct 13;65(19):12838-12859. doi: 10.1021/acs.jmedchem.2c00673. Epub 2022 Sep 25. J Med Chem. 2022. PMID: 36153841

10

Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents.

Liu X, Wang X. Liu X, et al. Chin J Nat Med. 2022 Nov;20(11):814-829. doi: 10.1016/S1875-5364(22)60238-3. Chin J Nat Med. 2022. PMID: 36427916 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138,299 results

Search Page

Filters